About this Research Topic
Multidrug-resistant (MDR) ESKAPE infections generally require extensive treatment procedures. Every ESKAPE pathogen has a wide range of infection and pathogenesis mechanisms, which has resulted in the development of resistance to several antibiotics. These bacteria can acquire resistance due to several efflux pumps, enhanced biofilm production, and low cell wall permeability, horizontal gene transfer and plasmids etc. To combat this issue different combinational therapies are used and in recent years, there has been significant progress using in vitro, in vivo, and computational methodologies to interrogate combination drug effects.
There is a significant increase in different types of combinational therapies being used for the treatment of MDR-ESKAPE pathogens. However, ESKAPE pathogens are deadly bacteria with rapidly growing multidrug-resistant properties, making them extremely hard to treat. We need to evolve treatment options rapidly with the changing response of the ESKAPE pathogen to a particular therapy. This can only be done if we understand all the possible mechanisms a pathogen uses for developing resistance to a particular type of therapy. This collection will be a platform where researchers can update their findings that have been used recently for the treatment of MDR ESKAPE pathogens, which can further help the scientific community understand and evolve their therapies at a faster rate than the rate of resistance developed by ESKAPE pathogens.
The research topic “Advances in New Combinational Therapies for Treatment of MDR Pathogens” invites research and review articles on the given themes.
1. Use of synergistic combinations of antibiotics for the treatment of MDR pathogens
2. Anti-microbial peptides and their mechanism of action
3. Applications and limitations of nanoparticle therapies for the treatment of MDR
4. Phage therapy for the treatment of MDR pathogens
5. Immunomodulation for the Eradication of MDR Pathogens
There is a significant increase in different types of combinational therapies being used for the treatment of MDR-ESKAPE pathogens. However, ESKAPE pathogens are deadly bacteria with rapidly growing multidrug-resistant properties, making them extremely hard to treat. We need to evolve treatment options rapidly with the changing response of the ESKAPE pathogen to a particular therapy. This can only be done if we understand all the possible mechanisms a pathogen uses for developing resistance to a particular type of therapy. This collection will be a platform where researchers can update their findings that have been used recently for the treatment of MDR ESKAPE pathogens, which can further help the scientific community understand and evolve their therapies at a faster rate than the rate of resistance developed by ESKAPE pathogens.
The research topic “Advances in New Combinational Therapies for Treatment of MDR Pathogens” invites research and review articles on the given themes.
1. Use of synergistic combinations of antibiotics for the treatment of MDR pathogens
2. Anti-microbial peptides and their mechanism of action
3. Applications and limitations of nanoparticle therapies for the treatment of MDR
4. Phage therapy for the treatment of MDR pathogens
5. Immunomodulation for the Eradication of MDR Pathogens
Keywords: Antimicrobial resistance, multi-drug resistance, Antimicrobial peptides, Antibiotic Synergy, Phage Therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
